Schorge J O, Lee K R, Lee S J, Flynn C E, Goodman A, Sheets E E
Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts, 02115, USA.
Obstet Gynecol. 1999 Sep;94(3):386-90. doi: 10.1016/s0029-7844(99)00312-9.
To identify selection criteria for radical surgery in early cervical adenocarcinoma based on pretreatment clinical stage and correlation with high-risk surgical-pathologic factors.
One hundred seventy-five women with International Federation of Gynecology and Obstetrics (FIGO) clinical stage IB1 (n = 132) and IB2-IIA (n = 43) cervical adenocarcinoma were treated primarily at our institutions from 1982 to 1996. Histopathologic sections were reviewed by a gynecologic pathologist. Medical records were reviewed retrospectively and clinical follow-up was done.
The overall 5-year survival rate was 87% (95% confidence interval [CI] 81%, 93%) for stage IB1 and 61% (95% CI 46%, 77%) for stage IB2-IIA (P<.001). Adenosquamous cell type, deep cervical invasion, and lymph-vascular space invasion were significant independent high-risk surgical-pathologic factors that affected disease-free survival (each P<.002). One hundred fourteen (86%) of 132 stage IB1 patients and 19 (44%) of 43 stage IB2-IIA subjects were treated primarily with radical surgery. Lymph node metastases, lymph-vascular space invasion, adenosquamous cell type, deep cervical invasion, and positive surgical margins were more than twice as frequent in stage IB2-IIA patients who had radical surgery than in stage IB1 patients (each P <.05). Based on high-risk surgical-pathologic factors in 133 subjects who had radical surgery, postoperative radiotherapy was recommended for 18 (16%) of 114 stage IB1 patients and 18 (95%) of 19 stage IB2-IIA subjects (P<.001).
Radical surgery for FIGO clinical stage IB1 cervical adenocarcinoma and primary radiotherapy for stage IB2-IIA disease would largely avoid combined-modality therapy, thereby reducing treatment-related toxicity and cost.
基于术前临床分期及与高危手术病理因素的相关性,确定早期宫颈腺癌根治性手术的选择标准。
1982年至1996年期间,175例国际妇产科联盟(FIGO)临床分期为IB1期(n = 132)和IB2-IIA期(n = 43)的宫颈腺癌女性患者在我们机构接受了主要治疗。妇科病理学家对组织病理学切片进行了复查。对病历进行了回顾性审查并进行了临床随访。
IB1期患者的总体5年生存率为87%(95%置信区间[CI] 81%,93%),IB2-IIA期为61%(95% CI 46%,77%)(P<.001)。腺鳞癌类型、宫颈深层浸润和淋巴管间隙浸润是影响无病生存的显著独立高危手术病理因素(各P<.002)。132例IB1期患者中有114例(86%)和43例IB2-IIA期患者中有19例(44%)主要接受了根治性手术。接受根治性手术的IB2-IIA期患者中,淋巴结转移、淋巴管间隙浸润、腺鳞癌类型、宫颈深层浸润和手术切缘阳性的发生率是IB1期患者中的两倍多(各P <.05)。基于133例接受根治性手术患者的高危手术病理因素,建议114例IB1期患者中的18例(16%)和19例IB2-IIA期患者中的18例(95%)术后接受放疗(P<.001)。
FIGO临床分期为IB1期的宫颈腺癌采用根治性手术,IB2-IIA期疾病采用原发性放疗,将在很大程度上避免综合治疗,从而降低与治疗相关的毒性和成本。